Abstract: Objective To explore the clinical characteristics and risk factors of secondary infection in patients with acute myeloid leukemia (AML) after chemotherapy.Methods Patients with AML undergoing chemotherapy in a hospital from March 2021 to April 2022 were enrolled as the research objects. The secondary infection after chemotherapy was statistically analyzed. The infection characteristics and clinical characteristics in both groups were analyzed. Multivariate regression was used to analyze the risk factors of secondary infection in AML patients after chemotherapy.Results Among 186 AML patients, 114 cases were infected after chemotherapy, and the infection rate was 61.29%. Among 114 patients with AML secondary infection, 46 strains of pathogenic bacteria were isolated, In the 114 AML patients with secondary infection, there were 46 strains of pathogens, including 12 strains of Gram-positive bacteria (26.09%), 25 strains of Gram-negative bacteria (54.35%) and 9 strains of fungi (19.57%). Logistic regression analysis showed that age>40 years old (OR=2.265, 95%CI:1.155-4.441), diabetes mellitus (OR=4.529, 95%CI: 1.48-13.863), WBC≤1×109/L (OR=2.818, 95%CI: 1.246-6.375), agranulocytosis time>7 d (OR=2.454, 95%CI: 1.232-4.891) and ratio of bone marrow blast cells>50% (OR=2.908, 95%CI: 1.189-7.109) were all independent risk factors of secondary infection.Conclusion The incidence of secondary infection is high in AML patients after chemotherapy. Clinically, early prevention and symptomatic treatment can be carried out for patients with age>40 years old, diabetes mellitus, WBC ≤1×109/L, agranulocytosis time>7 d and ratio of bone marrow blast cells>50%.
刘敏,李琳洁. 急性髓系白血病患者化疗后继发感染的临床特征及危险因素分析[J]. 中国医院统计, 2022, 29(6): 424-427.
Liu Min, Li Linjie. Clinical characteristics and risk factors of secondary infection in patients with acute myeloid leukemia after chemotherapy. journal1, 2022, 29(6): 424-427.
[1]MALEKI BEHZAD M, ABBASI M, OLIAEI I, et al. Effects of lifestyle and environmental factors on the risk of acute myeloid leukemia: Result of a hospital-based case-control study[J]. J Res Health Sci, 2021, 21(3):e00525. DOI:10.34172/jrhs.2021.58.
[2]HWANG S M. Classification of acute myeloid leukemia[J]. Blood Res, 2020, 55(s1):S1-S4. DOI:10.5045/br.2020.s001.
[3]SHAHRABI S, GHANAVAT M, BEHZAD M M, et al. CD markers polymorphisms as prognostic biomarkers in hematological malignancies[J]. Oncol Rev, 2020, 14(2):466. DOI:10.4081/oncol.2020.466.
[4]RAFIEEMEHR H, CALHOR F, ESFAHANI H, et al. Risk of acute lymphoblastic leukemia: Results of a case-control study[J]. Asian Pac J Cancer Prev, 2019, 20(8):2477-2483. DOI:10.31557/apjcp.2019.20.8.2477.
[5]BR-CK O, DUFVA O, HOHTARI H, et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival[J]. Blood Adv, 2020, 4(2):274-286. DOI:10.1182/bloodadvances.2019000792.
[7]MULANOVICH V, KONTOYIANNIS D P. Acute myeloid leukemia and the infectious diseases consultant[J]. Leuk Lymphoma, 2018, 59(6):1284-1291. DOI:10.1080/10428194.2017.1365861.
[12]U M M, HAO X H, CONG L, et al. The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China[J].Medicine(Baltimore),2019,98(50):e18196. DOI:10.1097/MD.0000000000018196.
[16]BALLO O, TARAZZIT I, STRATMANN J, et al. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy[J]. PLoS One, 2019, 14(1):e0210991. DOI:10.1371/journal.pone.0210991.
[17]ALDOSS I, DADWAL S, ZHANG J Y, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents[J]. Blood Adv, 2019, 3(23):4043-4049. DOI:10.1182/bloodadvances.2019000930.
[20]LIEN M Y, CHOU C H, LIN C C, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study[J]. PLoS One, 2018, 13(6):e0197851. DOI:10.1371/journal.pone.0197851.
[21]HEINZ W J, BUCHHEIDT D, CHRISTOPEIT M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)[J]. Ann Hematol, 2017, 96(11):1775-1792. DOI:10.1007/s00277-017-3098-3.
[22]ARNOLD D E, MAUDE S L, CALLAHAN C A, et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients[J]. Pediatr Blood Cancer, 2020, 67(3):e28092. DOI:10.1002/pbc.28092.